
Opinion|Videos|July 31, 2024
The Heterogeneity of Prostate Cancer
Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
3
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
4
Urocross shows sustained benefit through 24 months post-removal
5















